Costs of Diagnosis, Treatment, and Follow Up of Patients with Acute Myeloid Leukemia in the Netherlands
- 1 February 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 10 (1), 187-192
- https://doi.org/10.1089/152581601750098499
Abstract
The aim of the study was to calculate the costs in various places of acute myeloid leukemia (AML). Patients less than 65 years old, who were treated for newly diagnosed AML were included. The cost analysis distinguished between diagnosis, treatment, follow-up (maximum of 2 years), and treatment of relapse. The treatment period was divided into remission induction and consolidation treatment, harvest of bone marrow (BM) or peripheral blood stem cells, and transplantation. The costs of diagnosis amounted to $3,167 (1995 US$). Remission-induction treatments cost on average $46,387 and harvest of bone marrow or peripheral blood stem cells costs $6,491. The costs of the transplantation varied between $25,531 and $44,087. Costs of follow-up amounted to $4,167. Relapse treatment, mainly consisting of reinduction therapy, costs on average $24,338. The total average weighted costs of AML patients amounted to $104,386. Treating AML patients is very expensive, and major reductions in costs are not expected in the next future. Considering efficacy and effectiveness, it seemed that choices based on costs could be made between several consolidation techniques and between a specific consolidation technique and/or palliative treatment.Keywords
This publication has 9 references indexed in Scilit:
- A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]Blood, 1996
- Post-Remission Treatment of Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Cost analysis of different phases of acute myeloid leukaemiaLeukemia Research, 1994
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Quality and cost in the palliative care of cancerBritish Journal of Cancer, 1992
- Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemiaBlood, 1992
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB studyBlood, 1982